The FDA’s review of seven peptides has sparked significant interest across the healthcare industry, with compounding pharmacies, telehealth companies, investors, and other market participants preparing for the possibility of expanded legal access to peptide compounding. As federal regulators consider whether to permit compounding of these peptides, businesses are evaluating the potential market opportunity while navigating ongoing questions surrounding FDA approval, manufacturing standards, supply chain readiness, and regulatory compliance.
In a recent Forbes article, Jesse Dresser explained that many companies are already positioning themselves for a potential shift in the regulatory landscape. Jesse noted that compounding pharmacies and telehealth companies are actively engaged in discussions with private equity and venture capital firms as investors look to capitalize on the emerging peptide market, highlighting the significant business interest surrounding these potential regulatory changes.
To learn more about the FDA’s review of these seven peptides and what the PCAC meeting could mean for compounding pharmacies, telehealth companies, healthcare providers, and the broader peptide industry, watch Frier Levitt’s webinar featuring Edgar Asebey and Jesse Dresser.
